Brokerages Set Arvinas, Inc. (NASDAQ:ARVN) Price Target at $59.93

Arvinas, Inc. (NASDAQ:ARVNGet Free Report) has received an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $59.93.

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Arvinas in a research report on Wednesday, February 28th. Wedbush boosted their target price on Arvinas from $33.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Citigroup cut Arvinas from a “buy” rating to a “neutral” rating and raised their price target for the company from $36.00 to $55.00 in a report on Wednesday, February 14th. Truist Financial reissued a “buy” rating and issued a $65.00 price objective on shares of Arvinas in a research note on Monday, March 25th. Finally, Barclays raised their target price on Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th.

View Our Latest Stock Analysis on Arvinas

Insiders Place Their Bets

In related news, insider Ronald Peck sold 1,699 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the transaction, the insider now directly owns 67,516 shares of the company’s stock, valued at approximately $3,176,627.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the transaction, the insider now owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the sale, the chief financial officer now owns 181,916 shares in the company, valued at approximately $8,559,147.80. The disclosure for this sale can be found here. Insiders have sold 8,597 shares of company stock valued at $404,489 in the last ninety days. 2.55% of the stock is currently owned by insiders.

Institutional Trading of Arvinas

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Arvinas by 9.6% during the second quarter. BlackRock Inc. now owns 4,903,469 shares of the company’s stock valued at $121,704,000 after acquiring an additional 427,871 shares during the last quarter. FMR LLC increased its position in shares of Arvinas by 10.6% during the 3rd quarter. FMR LLC now owns 4,868,295 shares of the company’s stock valued at $95,613,000 after purchasing an additional 466,667 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Arvinas by 5.3% during the 4th quarter. Vanguard Group Inc. now owns 4,851,390 shares of the company’s stock worth $199,683,000 after purchasing an additional 243,167 shares during the period. RTW Investments LP purchased a new position in shares of Arvinas in the 4th quarter worth about $173,427,000. Finally, Price T Rowe Associates Inc. MD grew its position in Arvinas by 42.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company’s stock valued at $157,731,000 after buying an additional 1,143,452 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Performance

NASDAQ ARVN opened at $39.04 on Wednesday. Arvinas has a twelve month low of $13.57 and a twelve month high of $53.08. The stock has a market cap of $2.66 billion, a PE ratio of -6.01 and a beta of 1.94. The firm has a 50-day simple moving average of $45.15 and a 200 day simple moving average of $32.91.

Arvinas (NASDAQ:ARVNGet Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($1.38). The business had revenue of ($43.10) million for the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. During the same quarter last year, the firm posted ($1.56) earnings per share. Research analysts forecast that Arvinas will post -5.92 earnings per share for the current fiscal year.

About Arvinas

(Get Free Report

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Featured Stories

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.